Segment and Related Information (Tables)

6 Months Ended

Dec. 31, 2014

Segment Revenue and Operating Income (Loss)

Segment revenue and operating income (loss) were as follows during the periods presented:


(In thousands)	Molecular diagnostics		Pharmaceutical & clinical services			Research			Total
Three months ended December 31, 2014:
Revenue	$	179,149		5,244			—		$	184,393
Depreciation and amortization		4,991		450			595			6,036
Segment operating income (loss)		59,017		(1,011	)		(21,664	)		36,342
Three months ended December 31, 2013:
Revenue	$	196,158		7,902			—		$	204,060
Depreciation and amortization		1,467		489			482			2,438
Segment operating income (loss)		98,233		1,052			(16,286	)		82,999
Six months ended December 31, 2014:
Revenue	$	343,656		9,574			—		$	353,230
Depreciation and amortization		9,969		899			1,122			11,990
Segment operating income (loss)		104,101		(2,794	)		(39,045	)		62,262
Six months ended December 31, 2013:
Revenue	$	389,144		17,383			—		$	406,527
Depreciation and amortization		2,830		989			992			4,811
Segment operating income (loss)		195,981		2,889			(32,967	)		165,903


	Three months ended					Six months ended
	December 31,					December 31,
(In thousands)	2014		2013			2014		2013
Total operating income for reportable segments	$	36,342	$	82,999		$	62,262	$	165,903
Interest income		85		1,330			140		2,691
Other		1,513		(185	)		1,416		(623	)
Income tax provision		13,909		33,784			23,805		62,146

Net income	$	24,031	$	50,360		$	40,013	$	105,825

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References+ Details